The Postoperative Recovery Course of Skeletal Muscle Mass in Older Esophageal Cancer Patients

IF 1.8 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES European Journal of Cancer Care Pub Date : 2023-04-28 DOI:10.1155/2023/6655999
Tsuyoshi Harada, Tetsuya Tsuji, N. Tatematsu, Junya Ueno, Yu Koishihara, Nobuko Konishi, Takumi Yanagisawa, Nanako Hijikata, Aiko Ishikawa, T. Fujita
{"title":"The Postoperative Recovery Course of Skeletal Muscle Mass in Older Esophageal Cancer Patients","authors":"Tsuyoshi Harada, Tetsuya Tsuji, N. Tatematsu, Junya Ueno, Yu Koishihara, Nobuko Konishi, Takumi Yanagisawa, Nanako Hijikata, Aiko Ishikawa, T. Fujita","doi":"10.1155/2023/6655999","DOIUrl":null,"url":null,"abstract":"Purpose. Skeletal muscle mass (SMM) is an important biomarker for health in older cancer patients. However, there is limited information on the recovery course of SMM after esophagectomy in older patients. This study aimed to investigate the recovery course of SMM after esophagectomy and the predictors in older cancer patients. Methods. We conducted a single-center, retrospective cohort study. Esophageal cancer patients who underwent esophagectomy were included. The skeletal muscle mass index (SMI) was calculated using computed tomography images. The loss of SMI at 4 and 12 months after surgery was calculated as [(preoperative − postoperative SMI) ÷ preoperative SMI] × 100%. Nonrecovery was defined as an SMI loss of ≥2% at 12 months after surgery, considering physiological loss with aging. One-way analysis of variance and multivariate logistic regression analysis was used for statistical analysis. Results. A total of 105 older (≥70 years) and 156 nonolder (<70 years) patients were analyzed. Older patients had a significantly larger loss of SMI 4 months (mean: 5.7% vs. 3.1%; \n \n p\n =\n 0.021\n \n ) and 12 months (mean: 1.0% vs. −1.4%; \n \n p\n =\n 0.040\n \n ) after surgery than nonolder patients. In older patients, the number of patients with nonrecovery of SMI at 12 months after surgery was 55 (52%). In older patients, significant predictors for the nonrecovery of SMI were preoperative sarcopenia (adjusted OR: 0.297; \n \n p\n =\n 0.012\n \n ), neoadjuvant chemotherapy (adjusted OR: 0.248; \n \n p\n =\n 0.015\n \n ), and loss of SMI 4 months after surgery (per 1%; adjusted OR: 1.076; \n \n p\n =\n 0.018\n \n ). Conclusions. It is suggested that older esophageal cancer patients have a larger unmet need for long-term postoperative loss of SMM than nonolder patients. Continuous outpatient rehabilitation, including exercise and nutritional therapy after discharge, which targets improvement in SMM at 4 months, may improve SMI at 12 months after surgery in older esophageal cancer patients.","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2023-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/6655999","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose. Skeletal muscle mass (SMM) is an important biomarker for health in older cancer patients. However, there is limited information on the recovery course of SMM after esophagectomy in older patients. This study aimed to investigate the recovery course of SMM after esophagectomy and the predictors in older cancer patients. Methods. We conducted a single-center, retrospective cohort study. Esophageal cancer patients who underwent esophagectomy were included. The skeletal muscle mass index (SMI) was calculated using computed tomography images. The loss of SMI at 4 and 12 months after surgery was calculated as [(preoperative − postoperative SMI) ÷ preoperative SMI] × 100%. Nonrecovery was defined as an SMI loss of ≥2% at 12 months after surgery, considering physiological loss with aging. One-way analysis of variance and multivariate logistic regression analysis was used for statistical analysis. Results. A total of 105 older (≥70 years) and 156 nonolder (<70 years) patients were analyzed. Older patients had a significantly larger loss of SMI 4 months (mean: 5.7% vs. 3.1%; p = 0.021 ) and 12 months (mean: 1.0% vs. −1.4%; p = 0.040 ) after surgery than nonolder patients. In older patients, the number of patients with nonrecovery of SMI at 12 months after surgery was 55 (52%). In older patients, significant predictors for the nonrecovery of SMI were preoperative sarcopenia (adjusted OR: 0.297; p = 0.012 ), neoadjuvant chemotherapy (adjusted OR: 0.248; p = 0.015 ), and loss of SMI 4 months after surgery (per 1%; adjusted OR: 1.076; p = 0.018 ). Conclusions. It is suggested that older esophageal cancer patients have a larger unmet need for long-term postoperative loss of SMM than nonolder patients. Continuous outpatient rehabilitation, including exercise and nutritional therapy after discharge, which targets improvement in SMM at 4 months, may improve SMI at 12 months after surgery in older esophageal cancer patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
老年食管癌患者术后骨骼肌质量的恢复过程
目的。骨骼肌质量(SMM)是老年癌症患者健康状况的重要生物标志物。然而,关于老年患者食管切除术后SMM的恢复过程的信息有限。本研究旨在探讨老年肿瘤患者食管切除术后SMM的恢复过程及其预测因素。方法。我们进行了一项单中心、回顾性队列研究。食管癌患者接受了食管癌切除术。使用计算机断层扫描图像计算骨骼肌质量指数(SMI)。术后4个月和12个月SMI损失计算为[(术前-术后SMI) ÷术前SMI] × 100%。未恢复定义为手术后12个月SMI损失≥2%,考虑到衰老的生理损失。采用单因素方差分析和多因素logistic回归分析进行统计分析。结果。共分析了105例老年(≥70岁)和156例非老年(<70岁)患者。老年患者4个月的SMI损失明显更大(平均:5.7% vs 3.1%;P = 0.021)和12个月(平均:1.0% vs. - 1.4%;P = 0.040)。在老年患者中,术后12个月SMI未恢复的患者为55例(52%)。在老年患者中,重度精神分裂症无法恢复的重要预测因素是术前肌肉减少(校正OR: 0.297;p = 0.012),新辅助化疗(调整OR: 0.248;p = 0.015),术后4个月SMI丢失(每1%;调整OR: 1.076;P = 0.018)。结论。这表明,老年食管癌患者比非老年食管癌患者有更大的未满足的术后长期SMM丢失需求。持续的门诊康复,包括出院后的运动和营养治疗,目标是在4个月时改善SMM,可能改善老年食管癌患者术后12个月的SMI。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European Journal of Cancer Care
European Journal of Cancer Care 医学-康复医学
CiteScore
4.00
自引率
4.80%
发文量
213
审稿时长
3 months
期刊介绍: The European Journal of Cancer Care aims to encourage comprehensive, multiprofessional cancer care across Europe and internationally. It publishes original research reports, literature reviews, guest editorials, letters to the Editor and special features on current issues affecting the care of cancer patients. The Editor welcomes contributions which result from team working or collaboration between different health and social care providers, service users, patient groups and the voluntary sector in the areas of: - Primary, secondary and tertiary care for cancer patients - Multidisciplinary and service-user involvement in cancer care - Rehabilitation, supportive, palliative and end of life care for cancer patients - Policy, service development and healthcare evaluation in cancer care - Psychosocial interventions for patients and family members - International perspectives on cancer care
期刊最新文献
Comparison of Nobiletin and 5-Demethylnobiletin as Cancer Chemopreventive Agents The Relationship Between Upper-Limb Lymphedema and Fatigue Among Breast Cancer Survivors Development Process of a Holistic Assessment Questionnaire to Measure and Monitor Cancer-Related Fatigue Faecal Immunochemical Testing in Symptomatic Primary Care Patients: A Diagnostic Accuracy Study Ferroptosis-Related LncRNA BCRP3 Promotes the Proliferation and Migration of Prostate Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1